Last reviewed · How we verify
Tafasitamab and Lenalidomide — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Tafasitamab and Lenalidomide (Tafasitamab and Lenalidomide) — Beijing InnoCare Pharma Tech Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tafasitamab and Lenalidomide TARGET | Tafasitamab and Lenalidomide | Beijing InnoCare Pharma Tech Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tafasitamab and Lenalidomide CI watch — RSS
- Tafasitamab and Lenalidomide CI watch — Atom
- Tafasitamab and Lenalidomide CI watch — JSON
- Tafasitamab and Lenalidomide alone — RSS
Cite this brief
Drug Landscape (2026). Tafasitamab and Lenalidomide — Competitive Intelligence Brief. https://druglandscape.com/ci/tafasitamab-and-lenalidomide. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing